Atlas›Domain XII · Complementary, energy & biofield›Guide 152
Guide XII-152

Laetrile (vitamin B17)

Ernst T. Krebs1845Russia
A 33 · L 53 · M 1412 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

Version followed: historical account of laetrile/amygdalin ("vitamin B17") as described by the US National Cancer Institute PDQ summary (last updated June 2022, no longer updated), the CAM-Cancer Collaboration summary (May 2026), the Cochrane review on laetrile for cancer, the 1981 Mayo Clinic pharmacology study, US FDA enforcement records, and EFSA and FSANZ food-safety statements. This is not a therapy a psychotherapist delivers or recommends, and it is not presented as a treatment for cancer or any other disease. Sections 1–3 describe what was sold and done so that clinicians can recognise it; section 5 sets out the psychotherapist's own work.

1. What it was

The substance and its names. Amygdalin is a plant compound of the cyanogenic glycoside group, found mainly in the seeds (kernels) of apricots, peaches and bitter almonds; when broken down by certain enzymes it releases cyanide [source: CAM-Cancer]. Three products are usually blurred together under one label [source: NCI PDQ]:

  • "Mexican" laetrile/amygdalin, made from crushed apricot pits;
  • the US-patented semisynthetic "Laetrile" (a glucuronide derivative);
  • "vitamin B-17", a marketing name. NCI states it was coined by E.T. Krebs Jr. and has never been approved by the American Institute of Nutrition's nomenclature committee; amygdalin is not a vitamin and is not needed for normal metabolism [source: NCI PDQ; CAM-Cancer].

Because products sold in the US and in Mexico differed chemically, and some Mexican products were simply crushed seeds, people who say they "took laetrile" may have taken quite different things [source: CAM-Cancer; NCI PDQ].

Who developed and promoted it, where and when.

  • Amygdalin was isolated by French chemists in 1830 and used against cancer in Russia in 1845 [source: NCI PDQ; CAM-Cancer].
  • In the US it was first used for cancer in the early 1920s as an oral pill, which was abandoned as too toxic. In the 1950s a supposedly non-toxic intravenous form was patented as Laetrile [source: NCI PDQ]. CAM-Cancer attributes this development to "Ernst T. Krebs"; the cited sources do not settle the respective roles of Ernst T. Krebs Sr. and Jr. [uncertain: not verified]. CAM-Cancer reports that some proponents and suppliers, "including Krebs", received prison sentences [source: CAM-Cancer; details uncertain: not verified].
  • 1970: the McNaughton Foundation's investigational new drug application to the FDA was first approved, then rejected because animal data showed little anticancer effect and the study design was questioned. Supporters presented this as government obstruction; court challenges followed in Oklahoma, Massachusetts, New Jersey and California, and laetrile was legalised in more than 20 US states during the 1970s. By 1978 more than 70,000 Americans were reported to have been treated [source: NCI PDQ].
  • 1980: the US Supreme Court upheld the federal ban on interstate shipment. Use declined but continued, mainly in Mexico and at some US clinics [source: NCI PDQ].
  • 1980: the actor Steve McQueen, who had mesothelioma, travelled to Rosarito Beach, Mexico, for a regimen devised by William D. Kelley, a dentist whose Texas licence had been suspended. The regimen included laetrile. McQueen died in November 1980 after surgery; before then, press conferences in Mexico had presented patients as cured and a Mexican physician claimed most patients improved [source: Lerner, New York Times essay 2005, reposted on author's site].
  • 2000s: Jason Vale, through his company Christian Brothers Contracting Corporation, sold laetrile/amygdalin, "Vitamin B-17" and apricot pits online as a cancer treatment and preventive, including by spam email promising a "cancer free life". He kept selling after a 2000 court injunction and a consent decree, via a shell company, and was convicted of criminal contempt in 2003 and sentenced in 2004 to 63 months in prison [source: FDA Court Sentencings 2003; SupplySide Supplement Journal report of FDA announcement].
  • Today: amygdalin continues to be manufactured and given, mainly in Mexico and at some US clinics [source: NCI PDQ]; raw and "bitter" apricot kernels are sold, often online, and promoted as cancer-fighting food [source: EFSA 2016; FSANZ].

Stated rationale (as proponents held it; none is supported). NCI and CAM-Cancer describe four proposed theories [source: NCI PDQ; CAM-Cancer]:

  • Trophoblastic theory: cancer cells were said to have more of an enzyme that releases cyanide from laetrile and less of the enzyme (rhodanese) that detoxifies cyanide, so the poison would act selectively on tumours. The trophoblastic theory of cancer itself is not accepted.
  • Beta-glucosidase theory: a variant of the same selective-release idea.
  • Vitamin-deficiency theory: cancer is a metabolic deficiency disease and "B17" corrects it. Supporters cited reports of long-lived, cancer-free populations (e.g. the Hunza) with high kernel intake; CAM-Cancer describes these reports as methodologically flawed and non-causal.
  • Lysosome theory: released cyanide acidifies tumours and damages lysosomes, killing cancer cells and stimulating immunity.

How it was sold to patients and referrers. As a natural, non-toxic vitamin; as a suppressed cure blocked by government and the cancer establishment (the framing that accompanied the 1970s court and state-legislative campaigns); through celebrity cases and clinic press conferences presenting cured patients; later through websites, spam and online shops selling kernels and tablets [source: NCI PDQ; Lerner 2005; FDA 2003]. The FDA's acting commissioner said at Vale's sentencing that laetrile offers nothing "but false hope to cancer patients" [source: SupplySide report of FDA announcement].

2. What was actually done

The sequence below describes a typical course as the sources report it. Administration is described qualitatively only.

  1. Selection. People with cancer, often advanced, or people fearing cancer, were recruited through word of mouth, books and magazines, celebrity stories, clinic publicity and, later, websites and email [source: NCI PDQ; Lerner 2005; FDA 2003]. Many had been told by oncologists that standard treatment could not cure them; others chose it before or instead of standard treatment. The FDA reported that some patients used laetrile in place of conventional treatment until that treatment could no longer help [source: SupplySide report of FDA announcement]. Detailed descriptions of clinic intake assessment are [uncertain: not verified].
  2. Consent. Patients were offered a "natural vitamin" with a scientific-sounding mechanism and told it was being suppressed; the chemical identity, cyanide release and absence of trial evidence were not part of that offer as the sources describe the marketing [source: NCI PDQ; FDA 2003]. Formal consent procedures at clinics are [uncertain: not verified].
  3. Setting. Clinics in Mexico (for example Rosarito Beach, where Steve McQueen was treated) and some US clinics; later, home use of tablets or kernels bought by mail or online [source: NCI PDQ; Lerner 2005; FDA 2003; EFSA 2016].
  4. Injection phase. Usually an initial course of intravenous (or intramuscular) laetrile given repeatedly at the clinic [source: NCI PDQ; CAM-Cancer].
  5. Oral maintenance. Then tablets taken at home over the longer term; in Mexico, products might be crushed apricot seeds; many people ate raw bitter apricot kernels [source: NCI PDQ; CAM-Cancer]. Oral use carries far greater cyanide risk than injection (see section 3).
  6. Other routes. Enemas and direct application to skin lesions were also reported [source: CAM-Cancer].
  7. "Metabolic therapy" package. Laetrile was commonly combined with a restrictive diet, high-dose vitamin supplements and pancreatic enzymes [source: NCI PDQ; CAM-Cancer]. In the regimen given to Steve McQueen, as reported, the components also included many daily vitamin and mineral pills, coffee enemas, injections of cell preparations from sheep and cattle fetuses, massage, prayer sessions and psychotherapy [source: Lerner 2005]. Combination with high-dose vitamin C appears in poisoning case reports [source: CAM-Cancer].
  8. Judging "progress". Proponents relied on anecdotes, testimonials and symptomatic improvement; NCI's 1978 case review found that many claimed regressions in early series followed radiotherapy or chemotherapy rather than laetrile [source: NCI PDQ]. In the 1982 trial, some patients reported feeling better or having fewer symptoms in the short term, but these benefits did not persist and tumours progressed [source: NCI PDQ]. How clinics handled non-response or refusal is [uncertain: not verified]; within the suppressed-cure framing, failure was easy to attribute to starting too late or prior conventional treatment [synthesis].

Named variants. Mexican crushed-pit amygdalin; US semisynthetic Laetrile; "vitamin B17" tablets; raw or "bitter"/"Himalayan" apricot kernels sold as food; amygdalin as one element of Kelley-style and other "metabolic" regimens [source: NCI PDQ; CAM-Cancer; Lerner 2005; FSANZ].

How it was tested. NCI-sponsored rodent studies (published 1975) found no response in solid tumours or leukaemia and no meaningful survival gain [source: NCI PDQ]. A Mayo Clinic pharmacology study of six patients with advanced cancer (Moertel et al., JAMA 1981) found injected amygdalin was mostly excreted unchanged, while oral amygdalin raised blood cyanide; the authors concluded that "a definite hazard of cyanide toxic reaction must be assumed" [source: JAMA 1981 abstract]. The NCI-sponsored phase II trial (Moertel et al., N Engl J Med 1982;306(4):201–206), in patients with cancers such as breast, colon and lung who had had no other therapy for at least a month, gave intravenous amygdalin followed by oral amygdalin with vitamins, pancreatic enzymes and diet. Of 175 evaluable patients, one had a partial response lasting 10 weeks; 54% had measurable progression by the end of the intravenous phase and all had progressed by seven months; blood cyanide rose during oral therapy [source: NCI PDQ]. CAM-Cancer reports that some blood cyanide levels approached the lethal range [source: CAM-Cancer]. No randomised trial has ever been done; the Cochrane review found none and judged the risk–benefit balance "unambiguously negative" [source: Cochrane review, translated page; CAM-Cancer].

3. How it caused harm

Cyanide poisoning (direct harm).

  • Mechanism: amygdalin is split by beta-glucosidase enzymes into hydrogen cyanide and benzaldehyde. Gut bacteria contain these enzymes, which is why oral use is far more dangerous than injection; raw almonds, some plants and preparations made from apricot seeds also supply the enzyme [source: NCI PDQ; CAM-Cancer]. Risk is further raised by high-dose vitamin C, by reduced ability to detoxify cyanide, and in vegetarians with vitamin B12 deficiency [source: Cochrane review; CAM-Cancer]. Tolerance varies so much between individuals that personal risk cannot be predicted [source: CAM-Cancer].
  • Symptoms: headache, dizziness, nausea, vomiting, fever, thirst, lethargy, nervousness, joint and muscle pain, falling blood pressure, skin reactions; in severe cases confusion, rapid heart rate, breathing difficulty, liver damage, nerve damage with difficulty walking, coma and death [source: NCI PDQ; CAM-Cancer; EFSA 2016].
  • Documented cases: in the 1981 Mayo study, a patient who ate raw almonds during oral treatment developed cyanide toxicity symptoms (the abstract reports one patient; NCI and CAM-Cancer report two) [uncertain: sources differ]. Deaths were attributed to amygdalin preparations in reports from 1978 and 1979; a 1982 report described near-fatal poisoning with recovery; a 2005 Australian report described life-threatening poisoning in a woman taking amygdalin with high-dose vitamin C; a 2015 report described severe brain injury (encephalopathy) in a four-year-old child given oral and intravenous amygdalin; a 2022 report described poisoning in a 72-year-old man with cancer after an amygdalin supplement; a 2019 study of 55 tumour patients found blood cyanide rose significantly after intravenous amygdalin on top of chronic oral use [source: CAM-Cancer]. In Australia, people were hospitalised after eating raw apricot kernels in Queensland (2011) and Western Australia (2014); poisonings were also reported in New Zealand, Canada, the UK and Europe [source: FSANZ].
  • Most at risk: children (EFSA states toddlers may exceed safe levels from a single small kernel) [source: EFSA 2016]; people taking oral products or eating kernels, especially with vitamin C supplements; people with liver impairment; pregnant and breastfeeding women, for whom use is contraindicated [source: CAM-Cancer; Cochrane review].

Product harms. Mexican products were found mislabelled and contaminated with bacteria; samples have contained toxins and other substances; products bought online come from questionable sources [source: NCI PDQ; CAM-Cancer; Cochrane review].

Indirect harm: lost treatment time. The greatest harm reported by the FDA was patients using laetrile instead of conventional treatment until that treatment could no longer work [source: SupplySide report of FDA announcement]. In the 1982 trial, all patients' cancers progressed [source: NCI PDQ].

Financial harm. Patients paid for travel, clinic stays, injections and ongoing supplies; the FDA reported that one seller made at least $500,000 from illegal sales [source: SupplySide report of FDA announcement]. Clinic costs are [uncertain: not verified].

Psychological sequelae. The sources document "false hope" [source: FDA]. The following are clinical inferences, not documented in the cited sources [synthesis]: hope invested in a "cure" followed by collapse when disease progressed; guilt and self-blame in patients who delayed treatment; complicated grief, anger and regret in families, sometimes directed at relatives who encouraged the choice; family splits between pro- and anti-laetrile members; mistrust of medicine that makes later palliative engagement harder; shame about money spent; and, in the bereaved, intrusive "what if" rumination.

Diet-related risk. The "metabolic therapy" diets were restrictive [source: NCI PDQ]; in people with cancer-related weight loss, restrictive regimens risk malnutrition, and in people with eating-disorder histories they can reinforce restriction [synthesis; see Domain II eating-disorder entries].

4. Recognising it today

Names and products. "Vitamin B17" or "B-17"; amygdalin; laetrile; "bitter", "raw" or "Himalayan" apricot kernels or seeds; apricot-kernel powders, tablets, capsules or extracts; amygdalin injections or infusions offered by integrative or "biological" clinics, including as part of an infusion programme [source: NCI PDQ; CAM-Cancer; FSANZ; EFSA 2016]. A client may mention kernels as a "food" rather than a treatment; the 2016 EFSA statement notes kernels are mostly imported and sold online, with sellers sometimes recommending high daily intakes [source: EFSA 2016].

Phrases and rationales to listen for [source: NCI PDQ; CAM-Cancer; FDA 2003; synthesis for the paraphrased phrasings]:

  • cancer as a "vitamin deficiency", or B17 as the "missing vitamin";
  • cyanide that "only kills cancer cells" because tumours lack the detoxifying enzyme;
  • "natural chemotherapy", "metabolic therapy", "trophoblast" talk;
  • populations said never to get cancer because they eat kernels (Hunza and others);
  • "banned because it can't be patented", "the cure they don't want you to know about", appeals to the 1970s court battles or to celebrity patients;
  • a promise of a "cancer free life" (the phrase used in one convicted seller's spam) [source: FDA 2003].

Settings and routes. Cross-border clinics in Mexico; some US clinics; online shops and social-media sellers; "wellness" retreats and supplement distributors; packages bundling amygdalin with high-dose vitamin C infusions, enzymes, restrictive diets or enemas [source: NCI PDQ; CAM-Cancer; synthesis for retreats and social media]. Combined vitamin C and amygdalin is a specific danger signal (section 3).

Regulatory status (useful when a client says it is "legal").

  • USA: not approved; the FDA bans its use and has prosecuted sellers; interstate shipment ban upheld by the Supreme Court in 1980 [source: NCI PDQ; CAM-Cancer; FDA 2003].
  • UK: the MHRA classes amygdalin/laetrile/B17 as a prescription-only medicine; no licensed product exists, so supply other than an unlicensed prescription by a doctor at their own risk is unlawful [source: CAM-Cancer; legal implication is synthesis].
  • EU: not authorised as a medicine; Germany treats amygdalin medicines as unsafe; EFSA warned in 2016 about cyanide from raw kernels [source: Cochrane review; CAM-Cancer; EFSA 2016].
  • Australia and New Zealand: sale of raw apricot kernels prohibited under the Food Standards Code since 2015 [source: FSANZ].

Red flags in a colleague's or service's practice [synthesis]:

  • recommending, selling or referring to kernels, B17 or amygdalin clinics, or earning commission from such clinics;
  • describing laetrile as "complementary" while advising delay or refusal of oncology care;
  • discouraging a client from telling their oncologist;
  • presenting testimonials or celebrity stories as evidence;
  • framing disease progression as the client's failure to comply or to "believe";
  • counselling a family to give kernels or amygdalin to a child.

How legitimate practice differs. Integrative oncology, as its professional societies describe it, uses evidence-informed complementary approaches alongside standard treatment, never instead of it, and discloses everything to the oncology team (see entry 172) [cross-reference; not verified here]. Legitimate research on plant compounds happens in registered trials with ethics approval and consent that explains known toxicity; no such trial supports laetrile [source: Cochrane review; NCI PDQ]. Supportive psychotherapy within cancer care (psycho-oncology) addresses fear, meaning and decision-making without promising cure [synthesis].

5. What to do instead and how to help those harmed

Recommended alternatives. Care from the client's oncology team (surgery, radiotherapy, systemic therapy and clinical trials as offered there); early palliative and supportive care; integrative oncology as its professional societies define it, alongside standard care (entry 172); psycho-oncology and psychotherapy for fear, uncertainty and decisions [source: NCI PDQ and Cochrane review for the absence of benefit; alternatives named as synthesis]. The psychotherapist never performs, sells, prescribes, recommends or sources laetrile, amygdalin or kernels, and never advises starting, stopping or changing any medicine or supplement; such questions go to the prescriber or pharmacist [synthesis].

The interventions below are the psychotherapist's own work. Unless a source is given, they are [synthesis] drawn from general psycho-oncology and decision-support practice, not from the laetrile literature.

5.1 Routine, non-judgemental inquiry and recording

  • Purpose / when: at assessment and at each change in medical situation (new diagnosis, recurrence, end of treatment, "nothing more we can do" conversations) [synthesis].
  • Steps: ask about all treatments, supplements, foods taken for health, clinics and online purchases, normalising the question; ask specifically about "B17", apricot kernels, amygdalin and infusions if cancer is present; record product, route (oral, kernels, injection), source and whether the oncology team knows; note vitamin C supplementation alongside [synthesis; risk factors from CAM-Cancer and Cochrane review].
  • Example language (illustrative): "Many people with cancer try things outside their hospital treatment. Are you taking or considering anything like that? I ask everyone, and I won't judge." / "Some people hear about apricot kernels or vitamin B17. Has that come up for you?"
  • Watch for: guarded answers, "it's just food", secrecy from the oncologist, a relative supplying products. It is working when the client discloses freely and returns to the topic unprompted.

5.2 Exploring meaning, hopes and the explanatory model

  • Purpose / when: once use or interest is disclosed; before any discussion of risk [synthesis].
  • Steps: ask what they have heard and from whom; what they hope it will do; what it means (control, hope, avoiding chemotherapy side effects, distrust of doctors, faith, family or community identity, a story about a celebrity or friend); how they understand their cancer; what the oncologist has said and how that felt. Reflect without correcting first.
  • Example language (illustrative): "What draws you to it?" / "If it worked the way you hope, what would be different?" / "It sounds like it gives you something to do when you've felt powerless."
  • Watch for: hopelessness about standard care, recent bad news, conspiracy beliefs that also shape trust in you, pressure from others. Working: the client can name the needs behind the choice, which can then be met in other ways.

5.3 Autonomy-respecting decision support

  • Purpose / when: when a client (or family) is weighing laetrile against, alongside or after standard care.
  • Steps: (1) Confirm adults' right to decide. (2) Ask permission to share information. (3) Offer, in plain words, what independent bodies state: no anticancer benefit was found in the NCI-sponsored trial or in any controlled trial; cyanide poisoning is a documented risk, greater with oral use, kernels and vitamin C; products are often contaminated or mislabelled [source: NCI PDQ; Cochrane review; CAM-Cancer]. (4) Elicit their values and what matters most in the time ahead. (5) Help them prepare questions for the oncologist (e.g. what standard treatment offers them, what happens if they delay). (6) Make clear your support continues whatever they decide. No published decision aid specific to laetrile is drawn on here; use general shared-decision-making structure [uncertain: not verified].
  • Example language (illustrative): "Would it help if I told you what cancer agencies have found? You can tell me what you make of it." / "This is your decision. My job is to help you make it with all the information, and to keep supporting you either way."
  • Watch for: debating or persuading (raises resistance); collusion (agreeing it is safe). Working: the client can state the trade-offs in their own words and has a plan to discuss them with their doctor.

5.4 Coordination with the oncology, palliative and primary-care team

  • Purpose / when: whenever a client with cancer uses or plans to use laetrile or kernels, or is delaying treatment.
  • Steps: seek consent to inform the oncologist, GP or pharmacist; encourage the client to disclose themselves first; share only what is needed (product, route, vitamin C use, delay of treatment); ask the team about palliative referral if appropriate; document consent and communications.
  • Example language (illustrative): "Your oncologist needs to know about this to keep you safe, especially because of the risk of cyanide. Would you tell them, or would you like me to with your permission?"
  • Watch for: refusal of consent (respect it unless a safeguarding or imminent-risk threshold is met; consult your professional body or supervisor). Working: the medical team knows and the client stays engaged with them.

5.5 Recognising and responding to acute risk

  • Purpose / when: any session with a client using amygdalin or kernels.
  • Steps: know the warning signs of cyanide poisoning (headache, dizziness, nausea, vomiting, confusion, rapid heartbeat, breathing difficulty, falling blood pressure, collapse) [source: CAM-Cancer; EFSA 2016]; if present, arrange emergency medical care immediately (emergency services or poison centre). Do not assess or advise on the substance yourself.
  • Example language (illustrative): "What you're describing could be poisoning. I want you to get medical help now. Let's call together."
  • Watch for: symptoms dismissed as "detox" or "the cancer dying". Working: rapid medical contact.

5.6 Children, pregnancy and safeguarding

  • Purpose / when: a parent gives or plans to give a child kernels, B17 or amygdalin, or withholds medical cancer care from a child; a pregnant or breastfeeding client is using it.
  • Steps: treat a child given amygdalin or deprived of necessary medical care as a safeguarding concern; follow local child-protection procedures and consult the designated safeguarding lead. Toddlers are especially vulnerable (EFSA), and severe poisoning of a young child has been reported [source: EFSA 2016; CAM-Cancer]. For pregnancy and breastfeeding, where use is contraindicated [source: CAM-Cancer], coordinate with midwife or obstetrician with consent. Respect the child's assent and voice, appropriate to age.
  • Example language (illustrative): "I can see how much you want to protect them. Because kernels can poison children, I need to make sure their doctors are involved."
  • Watch for: concealment, group or online-community pressure on parents. Working: the child is under medical care and the parent stays in contact with you.

5.7 Grief, regret and guilt after choosing alternatives

  • Purpose / when: a client whose cancer progressed after delaying treatment, or a bereaved relative.
  • Steps: allow anger and regret without allocating blame; distinguish responsibility from culpability (decisions made under fear and misleading marketing); address "what if" rumination with standard grief-focused and self-compassion approaches; for complicated grief, consider evidence-based grief therapies (see relevant Domain entries).
  • Example language (illustrative): "You chose what you believed would save her, with the information you had. That was love, even though it hurts now."
  • Watch for: self-blame turning into depression or suicidal thinking (assess risk per standard practice); anger at doctors that blocks needed care. Working: the narrative shifts from blame to sorrow and meaning.

5.8 Family conflict

  • Purpose / when: relatives disagree over laetrile, or one relative supplies products against the patient's or others' wishes.
  • Steps: with consent, hold a family meeting focused on the patient's values and wishes; separate love and fear from method; agree on shared goals (comfort, time, honesty with the medical team); involve palliative or oncology staff where useful.
  • Example language (illustrative): "Everyone here wants the same thing for your dad. Can we start with what he wants?"
  • Watch for: coercion of the patient in either direction; scapegoating after death. Working: the patient's voice leads and the family can talk without blaming.

5.9 Financial harm

  • Purpose / when: clients who have spent heavily on clinics, travel or supplies, or face continued sales pressure.
  • Steps: name the loss and the shame; help the client prioritise and, where wanted, connect with debt advice, social work or consumer-protection routes; watch for repeated upsells and subscription supplies.
  • Example language (illustrative): "A lot of money went into hope. It makes sense that this hurts in more than one way."
  • Watch for: borrowing from family, crowdfunding pressure, sellers targeting the bereaved. Working: the client stops further spending and seeks practical help.

5.10 Distrust of medicine and repairing trust

  • Purpose / when: clients who believe in suppression narratives, or who feel let down by the medical system.
  • Steps: validate real experiences of feeling unheard; avoid ridicule; explore specific fears; help the client identify trustworthy people within their care; support preparing for consultations.
  • Example language (illustrative): "It sounds like you've felt dismissed before. What would help you feel heard by your doctors now?"
  • Watch for: rupture if you appear to side with "the system"; repair openly. Working: the client re-engages with at least one clinician.

5.11 Health anxiety and cancer fear without cancer

  • Purpose / when: people taking kernels or B17 for "prevention".
  • Steps: assess health anxiety; use established CBT-based approaches (see Domain II); share food-safety warnings on kernels [source: EFSA 2016; FSANZ].
  • Example language (illustrative): "It sounds like fear of cancer is driving this. Could we work on that fear directly?"
  • Watch for: reassurance-seeking, checking. Working: less preoccupation and stopping risky "prevention" in discussion with their GP.

5.12 Reporting

  • Purpose / when: you learn of illegal sale, false cancer-cure advertising, harm to a client, a child at risk, or a colleague recommending or selling laetrile.
  • Steps: with consent where required, report to the relevant regulator: US FDA (which has prosecuted laetrile sellers) [source: FDA 2003]; UK MHRA, which controls amygdalin as a prescription-only medicine [source: CAM-Cancer]; in Australia and New Zealand, food enforcement agencies for kernel sales [source: FSANZ, enforcement route uncertain: not verified]; advertising and consumer regulators; child-protection services for children; and professional boards for colleagues. Specific reporting forms and agency names beyond these are [uncertain: not verified]. Follow your profession's ethics code on avoiding harm, conflicts of interest and not selling products to clients [synthesis; uncertain: not verified against the APA Ethics Code].
  • Example language (illustrative): "I'm concerned this seller is putting other people at risk. Would you be willing for me to report it, or to report it yourself?"
  • Watch for: breaching confidentiality without a legal basis; consult supervision. Working: report made and documented.

Handling problems [synthesis]

  • Client insists on laetrile and refuses treatment: stay engaged, keep coordinating with consent, prioritise safety (oral and vitamin C risk) and comfort; offer palliative contact.
  • Client stops attending after you share risks: send a warm note; keep the door open.
  • Therapist's own frustration or fear: use supervision; avoid persuading or rescuing.
  • Client wants your endorsement: decline clearly and kindly; you do not recommend products.
  • Overwhelm on learning of harm: pace information, use grounding, and return to it later.

Sources

← Previous · XII-151Biohacking peptides and methylene blueNext · XII-153 →Hoxsey herbal treatment